Palo Alto – April 19, 2017 – Cooley advised FibroGen on its $120 million shelf takedown of 5,228,750 shares of common stock.
FibroGen, which is headquartered in San Francisco and trades on The NASDAQ Global Select Market as “FGEN,” is a research-based biopharmaceutical company using its expertise in connective tissue growth factor and hypoxia-inducible factor biology to discover, develop and commercialize novel therapeutics for serious unmet medical needs.
In 2014, Cooley advised FibroGen on its $167.7 million initial public offering.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.